Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis affecting the arteries in the lower extremities and is a major cause of morbidity and mortality in developed countries. It is considered a major marker for systemic ischemic events such as stroke and myocardial infarction (MI). Because asymptomatic patients make up a large percentage of the total PAD population, the disease is largely underdiagnosed, under-recognized, and undertreated. However, there is growing recognition that optimal management of PAD requires aggressive secondary prevention measures. Few drugs have been developed specifically for PAD, and the choice of therapies has changed little in recent years, but several novel therapies are in development. Increasing diagnosis and treatment rates, combined with substantial unmet need, make PAD a high-growth opportunity.

Questions answered

  • Generic competition dominates the PAD therapy market; sales of branded formulations are severely limited. What impact will the launch of novel branded drugs have on the PAD market? In which patients will these therapies likely be used?
  • R&D of novel PAD therapies have spanned a variety of mechanisms of action, but few therapies have demonstrated clinical benefit in PAD. How active is current drug development? What are thought leaders’ opinions of the prospects of therapies in development?
  • There is a substantial gap in the treatment of PAD; a considerable percentage of patients remain undiagnosed and untreated. How do thought leaders believe this treatment gap can be reduced? What effect will the introduction of new therapies have?

Product description

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with PAD experts.

Epidemiology: Prevalence of PAD by total population and severity; acute PAD-associated events; diagnosis status.

Population segments in market forecast: Asymptomatic, intermittent claudication, critical limb ischemia.

Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.

Market forecast features: We forecast drug sales for asymptomatic, intermittent claudication, and critical limb ischemia patient segments through 2027.

Table of contents

  • Disease Landscape and Forecast
    • COVID-19
    • Key Updates
      • June 2020
      • March 2020
      • December 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Peripheral Arterial Disease?
        • What Factors Are Constraining the Market for Peripheral Arterial Disease?
      • Drug-Class-Specific Trends
        • Antiplatelet Agents
        • Lipid-Lowering Agents
        • Antihypertensive Agents
        • Vasoactive Therapies
        • Prostaglandin Analogues
        • Anticoagulant Agents
        • Angiogenic Therapies
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Pathophysiology
        • Atherosclerotic Plaque Architecture
        • Atherosclerotic Plaque Rupture
        • Thrombus Formation
      • Disease Stages of Peripheral Arterial Disease
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases
        • Total Prevalent Cases by Severity
        • Diagnosed Prevalent Cases of Peripheral Arterial Disease
        • Drug-Treated Cases of Peripheral Arterial Disease
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Antiplatelet Agents
        • Thrombin Receptor Antagonists
        • Vitamin K Antagonists
        • Oral Factor Xa Inhibitors
        • ACE Inhibitors and ARBs
        • Beta Blockers
        • Calcium-Channel Blockers
        • Lipid-Lowering Therapies
        • Vasoactive Therapies
        • Prostaglandin Analogues
        • Nonpharmacological Approaches
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Peripheral Arterial Disease
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Stem Cell Therapies
        • PCSK9 Inhibitors
        • ACL Inhibitors
        • Angiogenic Gene Therapies
      • Early-Phase Pipeline Analysis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Peripheral Arterial Disease Bibliography

Author(s): Rameshwar Prajapati, Ph.D., M.S. (Pharm.); Devashri Mukherjee, MPH

Rameshwar Prajapati, (Pharm.), is a business insights analyst in Decision Resources Group’s cardiovascular, metabolic, renal, and hematologic disorders team, focusing primarily on obesity. In this role, his main function is to perform primary and secondary research related to obesity and its treatment, as well as providing insights and assessments for the major pharmaceutical markets regarding weight loss medications. Rameshwar holds a bachelor’s degree in pharmacy from Dr. Gour University, Sagar, India. He obtained his master’s and doctorate degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Nagar, India. Rameshwar also received a German Academic Exchange Service (DAAD) fellowship to conduct his research on P-glycoprotein at the University of Bonn, Germany.

Research enthusiast with a flair for academic writing, member of the DRG family since April 2015 and working from the India office. Started off career with a bachelor’s in Dental Surgery followed by a master’s in Public health; having primarily worked in the hospital setting as a Research Consultant prior to DRG and with 10 international publications to my credit.


Related Reports

Peripheral Arterial Disease | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key peripheral arterial di...

View Details

Peripheral Arterial Disease | Unmet Need | Detailed, Expanded Analysis (US & EU)

Market Outlook Peripheral arterial disease (PAD) is a complex manifestation of underlying atherosclerotic disease and is...

View Details